Momo Wakui

Dr. Momo Wakui

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2026 in Radiology Case Reports
Verified
Journal Article
Open access
JTJunichi Tsuchiya
Junichi Tsuchiya
XWXiaotong Wu
Xiaotong Wu
ATAnna Tabei
Anna Tabei
MWMomo Wakui
Momo Wakui
HYHirofumi Yamada
Hirofumi Yamada
UTUkihide Tateishi
Ukihide Tateishi

15 November 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
MWMomo Wakui
Momo Wakui
KYKota Yokoyama
Kota Yokoyama
HYHirofumi Yamada
Hirofumi Yamada
YKYusuke Kawasaki
Yusuke Kawasaki
HHHiroto Hada
Hiroto Hada
UTUkihide Tateishi
Ukihide Tateishi
Background/Objectives: Pulmonary iodine maps are routinely available from photon-counting detector computed tomography (PCD-CT), including examinations not optimized for pulmonary embolism (PE) assessment. We evaluated the frequency and contrast-phase distribution of pulmonary iodine map defects in routine clinical practice. Methods: This retrospective single-center study included 442 contrast-enhanced PCD-CT examinations in 433 patients during March–April 2026, each with whole-lung coverage in at least one postcontrast phase. Examinations were classified as dedicated pulmonary arterial, other whole-lung arterial, or nonarterial-only imaging. Two radiologists independently reviewed iodine maps followed by 70-keV virtual monoenergetic images, with disagreements resolved by consensus. Analyses were descriptive; no independent reference standard was available. Results: Iodine map defects were identified in 4/442 examinations (0.9%; 95% confidence interval, 0.2–2.3%), all corresponding to pulmonary arterial filling defects interpreted as PE. Defects occurred in 2/15 dedicated pulmonary arterial examinations and 2/70 other arterial examinations, versus 0/357 nonarterial-only examinations. In all three iodine-defect-positive examinations with paired later-phase imaging, iodine defects were no longer visible. Overall, PE was identified in 6/442 examinations (1.4%), including three findings absent from the original reports. Interobserver agreement was κ = 0.86 for iodine defects and κ = 0.83 for PE. Conclusions: Arterial-phase iodine maps may provide clues to PE on routine PCD-CT, even when acquisition is not timed to the pulmonary arterial phase. Absence of iodine defects on nonarterial images should not be used to exclude PE. Larger studies are needed to establish diagnostic benefit.

6 July 2026 in Intestinal Research
Verified
Journal Article
Closed access
AKAmi Kawamoto
Ami Kawamoto
KTKento Takenaka
Kento Takenaka
JTJunichi Tsuchiya
Junichi Tsuchiya
MWMomo Wakui
Momo Wakui
KOKazuo Ohtsuka
Kazuo Ohtsuka
RORyuichi Okamoto
Ryuichi Okamoto

2 July 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
MWMomo Wakui
Momo Wakui
SYShuichi Yanai
Shuichi Yanai
JTJunichi Tsuchiya
Junichi Tsuchiya
MYMasahide Yamamoto
Masahide Yamamoto
HYHirofumi Yamada
Hirofumi Yamada
UTUkihide Tateishi
Ukihide Tateishi
Systemic chronic active Epstein–Barr virus disease (sCAEBV) is a rare and potentially fatal disorder characterized by inflammatory manifestations and organ infiltration by EBV-infected T- or NK-cells. Although [18F]FDG PET/CT has limited utility for assessing the disease activity of sCAEBV, [11C]acetate PET/CT has not previously been evaluated in this setting. We therefore conducted this exploratory retrospective study to assess the utility of sequentially performed [11C]acetate and [18F]FDG PET/CT in sCAEBV. Five patients diagnosed with sCAEBV according to the criteria of the Research Group on Measures against Intractable Diseases, Ministry of Health, Labour and Welfare of Japan (consistent with the 2017 WHO classification) and assessed between July 2017 and December 2018 were included; patients younger than 20 years were excluded. Each patient underwent both [11C]acetate and 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) on the same day. The maximum and mean standardized uptake values (SUVmax and SUVmean) of the liver and spleen and the liver-to-spleen ratio (LSR) were correlated with laboratory parameters, including alanine aminotransferase (ALT) and lactate dehydrogenase (LDH), using Spearman’s rank correlation coefficient. The LSR was compared between active and inactive cases using the Mann–Whitney U test. Twenty-one lymph node regions were assessed in each patient, and the SUVmax of detected lesions was measured. The detection rate of lymph node lesions between the two tracers was compared using McNemar’s test, and the SUVmax of lymph node lesions was compared between the two tracers and between active and inactive cases using the Mann–Whitney U test. All statistical analyses were performed using R version 4.5.3 (R Foundation for Statistical Computing, Vienna, Austria), and a p-value < 0.05 was considered statistically significant. Five patients (three men and two women; mean age 31.8 years, range 21–39 years) were included. [11C]acetate PET/CT showed significant negative correlations between spleen SUV and liver enzymes (AST, ALT, and LDH), and significant positive correlations between the LSR and all five liver enzymes tested (AST, ALT, LDH, γGTP, and ALP) (Spearman’s rank correlation coefficient; p < 0.05 for all). No significant correlations were observed with [18F]FDG PET/CT. The LSR on [11C]acetate PET/CT was numerically higher in active cases than in inactive cases, though this difference was not statistically significant (0.88 ± 0.02 vs. 0.61 ± 0.02; p = 0.20, Mann–Whitney U test). Lymph node lesion detectability did not differ significantly between the two tracers (16 vs. 12 regions; p = 0.13, McNemar’s test). In this pilot study, [11C]acetate PET/CT spleen SUV showed significant negative correlations with liver enzymes (AST, ALT, and LDH), and the LSR showed significant positive correlations with all measured liver enzymes, suggesting that [11C]acetate PET/CT reflects both hepatic and splenic involvement in sCAEBV. [11C]acetate PET/CT may therefore serve as a novel imaging biomarker for assessing disease activity in sCAEBV, warranting further investigation in larger cohorts.